Daniel G. Teper

Biography

  Daniel G. Teper, Pharm.D., is Director of Immune Pharmaceuticals Inc. He had been appointed as Chairman of the Board, Chief Executive Officer from August 25, 2013 to December 15, 2014. Dr. Teper was the founder, Chairman and Chief Executive Officer of Immune Ltd. from January 2010 through the Merger. From 2005 to 2009, Dr. Teper was a New York-based Managing Partner and Head of North America at Bionest Partners. From 2000 until 2004, Dr Teper held various senior management roles in the United States including Senior Vice President of Sales and Business Development at Softwatch, an internet healthcare company, where he assisted in raising $30 million in venture capital and expanding the company to over 150 employees. Dr. Teper started his career in 1984 at the Novartis headquarters in Basel, Switzerland and then in the United States from 1985 until 1990 where he held management responsibilities in sales and marketing and eventually became the Head of New Product Development for Cardiovascular Products. From 1990 until 1992, Dr. Teper held general management positions in France, first as a Senior Vice President and Head of Marketing & Sales of Laboratories at GlaxoSmithKline, and then as President and Chief Operating Officer of Laboratories at Delagrange (which was acquired by Synthelabo, a predecessor to Sanofi). In 1993, Dr. Teper founded and was the CEO of WINTEC Pharma, a specialty pharmaceutical company. In 1995, Dr. Teper sold the anti-infectives segment of WINTEC Pharma to Norgine (UK) and the dermatology segment to Galephar (Belgium). In 1999, Dr. Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was a J. Salmon Scholar.

Research Interest

 pharmaceutical technologies business and management